Release date: 2015-06-09 According to an article published in the June issue of the American Journal of Gastroenterology Clinical Practice, Clinical Gastroenterology and Hepatology, the antiviral drug telbivudine prevents hepatitis B virus (HBV) during the perinatal period. Spread. "If we reduce the global incidence of hepatitis B, we need to address the mother-to-child transmission first, which is the main way of hepatitis B virus infection," research author Yuming Wang said. He is from the Institute of Infectious Diseases, Chongqing Southwest Hospital, China. "We found that telbivudine not only cuts off the way pregnant women pass the baby's hepatitis B virus vertically, but also that women and babies are well tolerated." The researchers conducted a prospective study of 450 HBV-positive pregnant women (they had very high viral levels in their bodies, or had very visible hepatitis B virus in their blood). The study took place in the last two or three of pregnancy. Within the month. During the study, 279 women received telbivudine (600 mg daily) between 24 and 32 gestational weeks, and 171 women were unwilling to take antiviral drugs as controls. Six months after the birth of the baby, none of the mothers taking telbivudine were tested positive for HBV, while 14.7% of the infants in the control group were tested positive for HBV. The level of hepatitis B virus in mothers has also decreased: nearly a quarter of women taking telbivudine have not detected hepatitis B virus in their bodies. Those who did not receive antiviral drugs were tested positive for hepatitis B virus. A large proportion of women taking telbivudine did not detect the HBV DNA content of umbilical cord blood (99.1%), which was lower than the HBV DNA content of the cord blood of the control group (61.5%). There were no serious adverse events or complications in women and infants during the study. The long-term effects of taking telbivudine remain to be explored relative to other recommended oral antiviral drugs such as tenofovir. Hepatitis B virus infects nearly two billion people worldwide and is the leading cause of liver disease. Source: Bio Valley Buckwheat Noodle,Homemade Buckwheat Soba Noodles,Organic Food Buckwheat Fine Noodle,Buckwheat Noodles Healthy Huantai Biotechnology Co., Ltd. , https://www.huantaifds.com